ASC-H on a scant, bloody smear with a 'negative' colposcopy
A 34-year-old woman who is HPV-16 positive has an ASC-H result on a liquid-based cervical cytology sample. The slide contains fewer than 20 abnormal squamous cells, no endocervical cells and abundant blood. Colposcopy is reported as 'no lesion seen', the squamocolumnar junction is fully visualised and endocervical curettage is negative. She has one prior co-test three years ago that was NILM and HPV negative, and no history of cervical treatment. The cytotechnologist who screened the slide is a locum on her third day in the laboratory, and the pathologist who signed it out is covering a colleague's service. The referring gynaecologist telephones to ask whether to proceed to LLETZ now or repeat co-testing in 12 months, and whether the cytology should be reviewed first.
1. How do you verify this ASC-H result before any management decision, and which morphological features actually matter?
Read the worked answer
Verify before advising. A diagnosis of ASC-H on a bloody, scant slide screened by an inexperienced locum and signed out by a covering pathologist is exactly the situation that demands a personal review rather than a telephone opinion.
Review steps:
- Retrieve and rescreen the slide; examine the bloody areas under higher power and cut deeper levels if the laboratory's protocol allows.
- Assess adequacy honestly: absence of endocervical/transformation-zone cells does not by itself make a smear unsatisfactory, but scant cellularity plus obscuring blood may.
- Look actively for the mimics of ASC-H: atrophy, repair, IUD effect, radiation change, and - critically - HSIL or adenocarcinoma in situ, which are undercalled as ASC-H more often than the reverse.
- Consider p16/Ki-67 dual stain on a residual ThinPrep vial to triage, and obtain a second opinion from a cytopathologist with gynaecological expertise.
Features that matter: high nuclear-to-cytoplasmic ratio in small, immature cells; irregular nuclear membranes; coarse hyperchromasia; and single cells or small syncytia. Nuclear enlargement with open chromatin and prominent nucleoli in a flat sheet suggests repair, not ASC-H.
Reality check on colposcopy: 'no lesion seen' with a fully visible junction lowers, but does not exclude, a high-grade lesion; a small lesion in the canal or under blood can be missed. The cytology report and the colposcopic impression must be reconciled, not simply averaged.
2. The gynaecologist asks: LLETZ now, or co-test in 12 months? Justify your recommendation with risk estimates and name the factors that would change it.
Read the worked answer
Risk framing. ASC-H is a high-risk category, not a borderline one. With HPV-16 positivity the immediate risk of CIN2+ at colposcopy is roughly a quarter, and the five-year risk of CIN3+ approaches half. This is well above the threshold at which observation alone with cytology is acceptable.
Both options are defensible under risk-based guidelines when colposcopy is adequate (fully visualised junction, negative endocervical curettage, no visible lesion): excisional treatment, or observation with co-testing at 12 months. The choice is a judgement call, not a single correct answer.
Factors favouring LLETZ here: HPV-16 positivity; a genuinely new infection after a documented HPV-negative co-test; a lesion that colposcopy may simply not be seeing; and any concern about follow-up reliability.
Factors favouring observation: age 34 with possible future fertility plans, no visible lesion, and the morbidity of excision (preterm birth risk, stenosis).
What I would not accept: a 3-year or 5-year return to routine screening. If she elects observation, it must be co-testing at 12 months and colposcopy for any abnormality; if she elects treatment, the specimen must be processed in a way that allows assessment of margins and the squamocolumnar junction. Document the discussion and the patient's preference - the medico-legal exposure lies in undocumented advice, not in choosing either option.
3. What laboratory quality-assurance actions does this case trigger?
Read the worked answer
Immediate:
- Mandatory second review of the slide by a designated cytopathologist, with the outcome recorded in the discrepancy log whether or not the diagnosis changes.
- Cytohistological correlation once the histology is available. If the biopsy shows CIN2/3, the case is a screening discrepancy and must be classified as such, not absorbed silently.
Systems issues:
- Locum competency documentation: has the locum completed the laboratory's screening test set, and is her work being rescreened at the higher rate required for new staff?
- Screening workload: confirm the daily limit per cytotechnologist (commonly 100 slides) and that the locum's rate was within it.
- Rescreening programme: random 10% rescreen plus targeted rescreen of high-risk categories (prior abnormal, HPV-positive, unsatisfactory) - check whether abnormal cases are being rescreened at all.
- Sign-out cover: a pathologist covering another service should not be signing out unfamiliar volumes without a defined review pathway.
Metrics to monitor and present at the monthly QA meeting:
- ASC-H rate and ASC/SIL ratio against benchmark.
- HPV-positive rate and cytology–histology concordance.
- Turnaround time and unsatisfactory rate.
Tone: the aim is educational and systemic. Individual blame suppresses reporting, which is the actual driver of harm; the goal is that the next locum's ASC-H is caught before the gynaecologist's phone call.